Ovarian Cancer Market Size Worth $20,067 Million By 2032 | CAGR: 23.5%

Ovarian Cancer Market Size Worth $20,067 Million By 2032 | CAGR: 23.5%

The global ovarian cancer market size is expected to reach USD 20,067 million by 2032, according to a new study by Polaris Market Research. The report “Ovarian Cancer Market Share, Size, Trends, Industry Analysis Report, By Type (Epithelial Tumors, Germ Cell Tumors, Stromal Tumors, Primary Peritoneal Cancer); By Diagnosis; By Therapeutic Treatment; By End-Use; By Region; Segment Forecast, 2023 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The global ovarian cancer market is expected to grow significantly in the coming years due to increased healthcare awareness among the population, advancements in medication for ovarian cancer treatment, and greater government support are driving the expansion of the market worldwide. Furthermore, approving new products is crucial in propelling the overall market growth.

Ovarian cancer is recognized as one of the most devastating cancers affecting women. It involves the abnormal proliferation of cells in the ovaries, which can spread to and adversely affect other organs such as the liver, lymph nodes, intestines, bladder linings, abdominal layers, and lymph nodes. In the early stages, this cancer may present with vague symptoms that become more noticeable as the disease progresses. These symptoms include bloating, pelvic pain, abdominal swelling, and loss of appetite.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below: https://www.polarismarketresearch.com/industry-analysis/ovarian-cancer-market/request-for-sample

Advancements in medication and treatment methods for ovarian cancer have also contributed to market growth. Pharmaceutical companies and research institutions are continuously working on developing innovative therapies that target ovarian cancer cells more effectively and have fewer side effects. These advancements include targeted therapies, immunotherapies, and precision medicine approaches, which hold great promise in improving patient outcomes and survival rates.

Government support has played a crucial role in driving the ovarian cancer market. Governments worldwide have recognized the need to address this significant health issue and have allocated funds for research, awareness campaigns, and improved healthcare infrastructure. This support has accelerated research and development efforts and increased access to quality healthcare services for patients.

Furthermore, the approval of new products is another key factor propelling the ovarian cancer market. Regulatory agencies have been working closely with pharmaceutical companies to streamline the approval process for novel therapies. This has resulted in a faster introduction of new drugs and treatment options, providing patients with more choices and improved outcomes.

Ovarian Cancer Market Report Highlights

  • Epithelial tumors segment accounted for the highest market share in 2022. Due to epithelial cancer, the most common form of ovarian cancer, begins in the tissue surrounding the ovaries and includes primary ovarian cancer and fallopian tube cancer.
  • Imaging techniques is expected to hold the fasted growth throughout forecast period, due to transvaginal ultrasonography is a commonly employed imaging technique for early detection and staging of ovarian cancer, allowing visualization and assessment of tumor size, especially for smaller tumors.
  • Hospital segment is anticipated to dominate the highest revenue share of the market. Due to increased hospital cases, heightened consumer awareness about cancer, and investments in healthcare infrastructure in developing and underdeveloped nations.
  • North America is anticipated to witness the significant growth during the forecast period. Due to The United States' gynecologic diagnostics market has experienced remarkable commercial success, driven by favorable government initiatives, increased healthcare spending, and the presence of key manufacturers, resulting in significant market growth.
  • The global key market players include Aetera Zenteris Inc., Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Roche Ltd., Genentech Inc., Pfizer Inc., Novogen, Inc., AstraZeneca Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Corp., GlaxoSmithKline plc, Johnson & Johnson Corp., Oasmia Pharmaceutical Inc., Tesaro Inc.

Polaris Market Research has segmented the ovarian cancer market report based on type, diagnosis, therapeutic treatment, end-use, and region:

Ovarian Cancer, Type Outlook (Revenue - USD Million, 2019 - 2032)

  • Epithelial Tumors
  • Germ Cell Tumors
  • Stromal Tumors
  • Primary Peritoneal Cancer

Ovarian Cancer, Diagnosis Outlook (Revenue - USD Million, 2019 - 2032)

  • Computed Tomography (C.T.) Scans
  • Ultrasound
  • Barium Enema X-Ray
  • Magnetic Resonance Imaging (MRI) Scans
  • Chest X-Ray
  • Positron Emission Tomography (PET) Scan
  • Other Diagnostic Tests

Ovarian Cancer, Therapeutic Treatment Outlook (Revenue - USD Million, 2019 - 2032)

  • Chemotherapy
  • Radiation Therapy
  • Targeted Therapy
  • Hormone Therapy
  • Other Therapeutic Treatments
  • Surgery

Ovarian Cancer, End-Use (Revenue - USD Million, 2019 - 2032)

  • Hospitals
  • Diagnostic Centers
  • Drug Stores
  • Online Pharmacies
  • Other End Users

Ovarian Cancer, Regional Outlook (Revenue - USD Million, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Ovarian Cancer Market Report Scope

Report Attributes


Market size value in 2023

USD 2,993 million

Revenue forecast in 2032

USD 20,067 million


23.5% from 2023 – 2032

Base year


Historical data

2019 – 2021

Forecast period

2023 – 2032

Quantitative units

Revenue in USD million and CAGR from 2023 to 2032

Segments Covered

By Type, By Diagnosis, By Therapeutic Treatment, By End-Use, By Region

Regional scope

North America, Europe, Asia Pacific, Latin America; Middle East & Africa


Report customization as per your requirements with respect to countries, region and segmentation.

For Specific Research Requirements

Request for Customized Report